J.DISCOVERY Solutions
for the identification of superior antibody therapeutics
J.HALSM is a revolutionary AI-driven discovery platform, producing diverse human antibodies with broad efficacy features biased toward developability, enabling rapid entry and success in the clinic. Using generative adversarial networks (GANs), J.HAL offers a new class of AI-derived antibodies – optimized for development, manufacturing, and in-use characteristics – better suited as biotherapeutics.
A highly efficient starting point for drug discovery and development projects across a broad range of indications.
The J.HAL Difference
- Fully human antibodies with broad diversity
- Designed and sequence-biased in silico for superior efficacy, efficiency, and developability features
- Lead discovery with decreased time and cost
Antibodies discovered with J.HAL can benefit from all of the integrated services of Just – Evotec Biologic’s J.DESIGN technology platform for biotherapeutic development
| Antibody Attribute | In Vivo Approaches | Traditional Libraries | J.HAL℠ Library |
| Description | Evolved for affinity | Designed for diversity in CDRs | Designed for diversity, humanness, and developability |
| Efficacy |  |
|
|
| Developability |  |
|
|
| Immunogenicity | |
|
|
| Speed | |
|
|
| Cost-Effective | |
|
|